NDA 011790 · Hikma
Robaxin
Methocarbamol · Im-Iv · Muscle Relaxant
Last checked: Nov 20, 2026Latest source record: Aug 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Jun 10, 1959
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
33
8 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Methocarbamol" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailurePivotal-lookingCompleted
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesIndustry
NCT00520806 · 1,161 participants · Start Oct 2007 · Primary completion Sep 2012
Drug: Relaxin; Placebo · For: Heart Failure, Congestive
Sites: Chicago, Illinois; Detroit, Michigan; Safed, Israel
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney InjuryPivotal-lookingRecruiting
River 2 Renal Corp.Industry
NCT07625553 · 430 participants (planned) · Start Apr 7, 2026 · Primary completion Apr 1, 2027
Drug: R2R01 · For: Acute Kidney Injury
Sites: Milan, Italy
- A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailurePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06299826 · 375 participants · Start Jun 4, 2024 · Primary completion Feb 10, 2026
Drug: AZD5462; Placebo · For: Chronic Heart Failure
Sites: Alexander City, Alabama; Northridge, California; Torrance, California · 57 sites in all
- Examining Analgesic Synergy and Efficacy in Trauma CarePivotal-lookingNot yet recruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07435077 · 282 participants (planned) · Start Mar 2027 · Primary completion Jul 2027
Drug: Buprenorphine; Oxycodone · For: Opioid Use Disorder
Sites: Winston-Salem, North Carolina
- Orphenadrine and Methocarbamol for LBPPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT02665286 · 240 participants · Start Mar 2016 · Primary completion Apr 2017
Drug: Orphenadrine; Methocarbamol and 2 more · For: Low Back Pain
Sites: The Bronx, New York
- Recombinant Human Relaxin in the Treatment of Diffuse SclerodermaPivotal-lookingCompleted
University of Medicine and Dentistry of New JerseyAcademic, hospital or other
NCT00704665 · 231 participants · Start Dec 1998 · Primary completion Dec 2001
Drug: Relaxin; Relaxin · For: Systemic Sclerosis
- Relaxin Therapy for Atrial FibrillationPivotal-lookingNot yet recruiting
Deeptankar DeMazumderFederal agency
NCT07359872 · 208 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2030
Drug: Relaxin; Placebo · For: Atrial Fibrillation (AF); Arrhythmia; Oxidative Stress and 5 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Does methocarbamol affect fatigue markers in the low-back electromyogram?
Boakes J, Peach JP, McGill SM · J Electromyogr Kinesiol 1998 · Clinical Trial, Comparative Study
- A controlled study of methocarbamol (Robaxin) in acute painful musculoskeletal conditions.
Tisdale SA, Ervin DK · Curr Ther Res Clin Exp 1975 · Clinical Trial, Randomized Controlled Trial
- Relief of acute musculoskeletal symptoms with intravenous methocarbamol (robaxin injectable): a placebo-controlled study.
Dent RW, Ervin DK · Curr Ther Res Clin Exp 1976 · Clinical Trial, Comparative Study
- Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.
Abd-Elsalam S, Arafa M, Elkadeem M, et al. · Eur J Gastroenterol Hepatol 2019 · Randomized Controlled Trial
- Muscle relaxants for pain management in rheumatoid arthritis.
Richards BL, Whittle SL, Buchbinder R · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.